St. Jude Medical: Results from quadripolar system study show cost savings St. Jude Medical announced that data presented during Heart Rhythm 2014, the Heart Rhythm Society’s Annual Scientific Sessions, found that the use of quadripolar leads reduced the number of hospitalizations by 53% when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62% reduction in overall costs for both health care systems and patients. The Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry presentation includes data that demonstrated hospitalization rates for the quadripolar group were lower than the non-quadripolar group and patients with the St. Jude Medical Quartet Quadripolar LV lead and had a 98% probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar left ventricular lead was associated with significantly reduced hospitalizations specific to the two types of hospitalizations studied: heart failure and LV lead surgical revision.
St. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.